REMS may be required during which part of the product life cycle?

REMS may be required during which part of the product life cycle?

• A. Before approval
• B. Only after approval
• C. Any time in the life cycle
• D. Never

Answer: (C)

Risk Evaluation and Mitigation Strategies (REMS) are regulatory tools used to ensure that the benefits of a medicine justify its risks, and they can be imposed at different points in a product’s life cycle depending on safety needs. The FDA can require a REMS as part of the approval decision, meaning controls are in place before patients can access the drug. They can also be added or updated after approval if new safety concerns emerge, or if ongoing use reveals risks that require additional safeguards. Because the requirement can arise at multiple stages—pre-approval, post-approval, or during modifications in response to safety data—the correct view is that REMS may be required any time in the life cycle.

Risk Evaluation and Mitigation Strategies (REMS) are regulatory tools used to ensure that the benefits of a medicine justify its risks, and they can be imposed at different points in a product’s life cycle depending on safety needs. The FDA can require a REMS as part of the approval decision, meaning controls are in place before patients can access the drug. They can also be added or updated after approval if new safety concerns emerge, or if ongoing use reveals risks that require additional safeguards. Because the requirement can arise at multiple stages—pre-approval, post-approval, or during modifications in response to safety data—the correct view is that REMS may be required any time in the life cycle.